Risdiplam Meets End Point, Fenfluramine Effective in Treating Dravet Syndrome, Rimegepant Sees Early Results in Migraine
CBD Under FDA Review, Rimegepant Meets Endpoint, Sleep-Disordered Breathing Associated With Alzheimer Disease
Cenobamate Gets Schedule V Designation, ICER Publishes Migraine Treatment Review, FDA Approves RNS System Labeling Update